Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma

In recent years, a number of targeted therapeutic agents have achieved success in phase III trials in patients with advanced hepatocellular carcinoma (HCC), including sorafenib, lenvatinib, and regorafenib. Immunotherapy is considered to be an effective treatment for advanced HCC. Immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Lin-Lin, Tao, Chang-Cheng, Tao, Zong-Gui, Zhang, Kai, Wu, An-Ke, Wu, Jian-Xiong, Rong, Wei-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554719/
https://www.ncbi.nlm.nih.gov/pubmed/34754383
http://dx.doi.org/10.4240/wjgs.v13.i10.1136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554719/
https://www.ncbi.nlm.nih.gov/pubmed/34754383
http://dx.doi.org/10.4240/wjgs.v13.i10.1136

Ejemplares similares